TRBV23-1: A Potential Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Target Name: TRBV23-1

NCBI ID: G28564

TRBV23-1

Other Name(s): TCRBV23S1 | T cell receptor beta variable 23-1 (non-functional) | TCRBV19S1P | TRBV231

TRBV23-1: A Potential Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by progressive lung airflow restriction and chronic inflammation. The TRBV23-1 gene, located on chromosome 6, has been identified as a potential drug target and biomarker for the treatment of COPD. This article will discuss the TRBV23-1 gene, its function, and its potential as a drug target in the treatment of COPD.

Introduction:

COPD is a chronic progressive lung disease that is characterized by airflow limitation and persistent inflammatory response. It is a leading cause of morbidity and mortality worldwide, with an estimated 17 million people in the United States alone suffering from COPD. COPD is caused by a combination of genetic and environmental factors, including the obstruction of airways, production of noxious substances, and an imbalance of pro-inflammatory and anti-inflammatory mediators.

TRBV23-1: A Potential Drug Target

The TRBV23-1 gene, located on chromosome 6, has been identified as a potential drug target for the treatment of COPD. The TRBV23-1 gene encodes a protein known as Tissue Response B cell voltage-dependent receptor B (TRBV23-1) ( 3). TRBV23-1 is a transmembrane protein that is involved in the regulation of cellular processes such as cell adhesion, migration, and signaling.

The TRBV23-1 gene has been shown to be involved in the regulation of pro-inflammatory and anti-inflammatory mediators in the airways of the lungs. It has been shown to play a role in the regulation of T-cell responses, which are critical for the development and progression of COPD.

The TRBV23-1 gene has also been shown to be involved in the regulation of cytokine production and the balance between pro-inflammatory and anti-inflammatory mediators. These cytokines are important for the regulation of cellular processes such as inflammation, fibrosis, and repair, and have been implicated in the development and progression of COPD.

TRBV23-1 as a Biomarker:

The TRBV23-1 gene has also been shown to be involved in the regulation of gene expression and protein levels in the airways of the lungs. This suggests that TRBV23-1 may be a useful biomarker for the diagnosis and monitoring of COPD.

The TRBV23-1 gene has been shown to be expressed in the airways of the lungs in individuals with COPD, and has been used as a potential biomarker for the diagnosis of COPD. In addition, the TRBV23-1 gene has been shown to be involved in the regulation of gene expression in T-cells, which are critical for the development and progression of COPD.

The TRBV23-1 gene has also been shown to be involved in the regulation of protein levels in the airways of the lungs, which may be an important target for the development of new COPD treatments.

Conclusion:

TRBV23-1 is a gene that has been identified as a potential drug target and biomarker for the treatment of COPD. Its function in the regulation of cellular processes such as cell adhesion, migration, and signaling, as well as its involvement in the regulation of pro-inflammatory and anti-inflammatory mediators, makes it an attractive target for the development of new COPD treatments. Further research is needed to

Protein Name: T Cell Receptor Beta Variable 23-1 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of T cell receptor (TR) beta chain (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive T cell receptor (TR) chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV23-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV23-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets